BriaCell Therapeutics Corp.’s (OTCQB: BCTXF) (TSX.V: BCT) Lead Candidate Shows Promising Anti-Tumor Activity in Proof of Concept Study
Company achieves positive proof of concept in Phase IIa study of its lead product candidate, Bria-IMT, in advanced breast cancer patients Efficacy data comparable to that of other approved breast cancer therapies in a similar stage of development Combination study with immune checkpoint inhibitors in the works, enrollment already open BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a clinical-stage biotechnology company focused on the development of proprietary targeted immunotherapy for advanced breast cancer, has achieved proof of concept and reported promising results from a Phase IIa study of its lead clinical candidate, Bria-IMT. Study data indicates promising anti-tumor activity for…